Inventiva (NASDAQ:IVA) Trading 4.8% Higher – Time to Buy?

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) traded up 4.8% during trading on Wednesday . The stock traded as high as $4.54 and last traded at $4.4650. 57,253 shares were traded during trading, a decline of 30% from the average session volume of 81,233 shares. The stock had previously closed at $4.26.

Analyst Ratings Changes

Several equities analysts have recently weighed in on IVA shares. Wall Street Zen upgraded shares of Inventiva to a “hold” rating in a research note on Saturday, October 18th. Wolfe Research raised shares of Inventiva to a “strong-buy” rating in a report on Thursday, November 6th. HC Wainwright lifted their price target on shares of Inventiva from $20.00 to $24.00 and gave the stock a “buy” rating in a research note on Thursday, October 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Inventiva in a research report on Wednesday, October 8th. Finally, Guggenheim decreased their target price on Inventiva from $13.00 to $11.00 and set a “buy” rating on the stock in a report on Tuesday, November 18th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $17.33.

Inventiva Price Performance

The business has a 50 day moving average price of $4.70 and a two-hundred day moving average price of $4.29.

Institutional Investors Weigh In On Inventiva

Institutional investors and hedge funds have recently modified their holdings of the stock. Wealth Enhancement Advisory Services LLC boosted its position in shares of Inventiva by 54.5% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 16,558 shares of the company’s stock worth $50,000 after acquiring an additional 5,843 shares during the last quarter. Creative Planning bought a new stake in Inventiva in the 2nd quarter valued at $32,000. NewEdge Advisors LLC purchased a new stake in Inventiva in the 3rd quarter worth $116,000. Finally, Millennium Management LLC bought a new position in shares of Inventiva during the 3rd quarter valued at about $649,000. Institutional investors own 19.06% of the company’s stock.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.